Healthy volunteers help uncover best way to take experimental drug calderasib

NCT ID NCT06619314

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study tested how food, different pill forms, and a common heartburn drug (a proton pump inhibitor) change the levels of the experimental drug calderasib in the blood. Fifty-six healthy adults each took a single dose of calderasib under various conditions. The goal was to gather basic information to guide future studies, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Calderasib (also known as MK-1084)
What this could lead to: If successful, this study will help determine the best way to take calderasib (with or without food, and with or without acid-reducing drugs) for future trials.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. The results only show how the drug is processed in the body, not whether it works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Celerion (Site 0001)

Lincoln, Nebraska, 68502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.